AC
FATE icon

AXQ Capital’s Fate Therapeutics FATE Stock Holding History

AXQ Capital’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$110K Buy
40,856
+30,150
+282% +$55.8K 0.01% 823
2026
Q1 		$12.8K Buy
+10,706
New +$13K ﹤0.01% 971
2024
Q2 		– Sell
-20,400
Closed -$150K – 536
2024
Q1 		$150K Buy
+20,400
New +$126K 0.04% 550
2023
Q2 		– Sell
-15,964
Closed -$91K – 390
2023
Q1 		$91K Sell
15,964
-52,175
-77% -$315K 0.04% 452
2022
Q4 		$688K Buy
+68,139
New +$1.28M 0.48% 65

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

AXQ Capital's FATE Position: Q2 2026 in Review

AXQ Capital increased its Fate Therapeutics (FATE) stake by 282% in Q2 2026, buying an estimated $55.8K and bringing the position to 40,856 shares worth $110K. The position accounts for 0.01% of the portfolio, ranked #823.

AXQ Capital first reported a position in FATE in Q4 2022 and has held it in 5 quarters since. The position peaked at $688K in Q4 2022. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • AXQ Capital held 40,856 shares of Fate Therapeutics worth $110K as of Q2 2026.
  • AXQ Capital bought 30,150 Fate Therapeutics shares in Q2 2026, an estimated $55.8K.
  • Fate Therapeutics made up 0.01% of AXQ Capital's portfolio in Q2 2026, its #823 holding.
  • AXQ Capital first reported a position in Fate Therapeutics in Q4 2022 and has held it in 5 quarters since.
  • AXQ Capital's Fate Therapeutics position peaked at $688K in Q4 2022.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.